Case Type: Mergers & Acquisitions

Amedisys, Inc. (NASDAQ: AMED), relating to its proposed merger with Option Care Health, Inc. Under the terms of the agreement, AMED shareholders are expected to receive 3.0213 share of Option Care per share they own.

Home Point Capital Inc. (NASDAQ: HMPT), relating to its proposed sale to Mr. Cooper Group Inc.

CTI Biopharma Corp, Inc. (NASDAQ: CTIC), relating to its proposed sale to Swedish Orphan Biovitrum AB. Under the terms of the agreement, CTIC shareholders are expected to receive $9.10 in cash per share they own.

Magellan Midstream Partners, L.P. (NYSE: MMP), relating to its proposed sale to ONEOK, Inc. Under the terms of the agreement, MMP shareholders are expected to receive $25.00 in cash and 0.6670 shares of ONEOK per share they own.

Magenta Therapeutics, Inc. (NASDAQ: MGTA), relating to its proposed merger with Dianthus Therapeutics, Inc. Under the terms of the agreement, MGTA shareholders are expected to own approximately 21.3% of the combined company

Arconic Corp. (NYSE: ARNC), relating to its proposed sale to affiliates of Apollo Global Management, Inc. Under the terms of the agreement, ARNC shareholders are expected to receive $30.00 in cash per share they own.

Enzo Biochem, Inc. (NYSE: ENZ), relating to its proposed sale to Laboratory Corporation of America Holdings.

Ruth’s Hospitality Group, Inc. (NASDAQ: RUTH), relating to its proposed sale to Darden Restaurants, Inc. Under the terms of the tender offer, RUTH shareholders are expected to receive $21.50 in cash per share they own.

Midwest Holding Inc. (NASDAQ: MDWT), relating to its proposed sale to Antarctica Capital. Under the terms of the agreement, MDWT shareholders are expected to receive $27.00 in cash per share they own.

IVERIC bio, Inc. (NASDAQ: ISEE), relating to its proposed sale to Astellas Pharma Inc. Under the terms of the agreement, ISEE shareholders are expected to receive $40.00 in cash per share they own.